Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.
Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J. Vardakis N, et al. Among authors: messaritakis i. Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11. Clin Cancer Res. 2011. PMID: 21071514
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: messaritakis i. PLoS One. 2011 Jan 20;6(1):e15980. doi: 10.1371/journal.pone.0015980. PLoS One. 2011. PMID: 21283802 Free PMC article.
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.
Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: messaritakis i. PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013. PLoS One. 2013. PMID: 24367680 Free PMC article.
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Koinis F, et al. Among authors: messaritakis i. Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16. Br J Cancer. 2017. PMID: 28510571 Free PMC article. Clinical Trial.
Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V. Milaki G, et al. Among authors: messaritakis i. Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18. Cancer Chemother Pharmacol. 2017. PMID: 28523597
57 results